ID   KYAE-1
AC   CVCL_1825
SY   KYAE1; KYAE
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 917
DR   cancercelllines; CVCL_1825
DR   Cell_Model_Passport; SIDM00530
DR   Cosmic; 1599341
DR   Cosmic-CLP; 1503368
DR   DepMap; ACH-001544
DR   DSMZ; ACC-703
DR   DSMZCellDive; ACC-703
DR   ECACC; 11012002
DR   EGA; EGAS00001000978
DR   GDSC; 1503368
DR   GEO; GSM1670014
DR   JCRB; JCRB1483
DR   PharmacoDB; KYAE1_798_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54900776
RX   PubMed=11520067;
RX   PubMed=20075370;
RX   PubMed=23795680;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: ~3-4 days (DSMZ=ACC-703).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Unspecified (PubMed=20075370).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=1.72%; East Asian, North=76.1%; East Asian, South=22.17%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=20075370
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 14,15
ST   D19S433: 14
ST   D21S11: 29,31
ST   D2S1338: 20
ST   D3S1358: 15,16
ST   D5S818: 10,13
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 18
ST   Penta D: 9,10
ST   Penta E: 5,8
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 12,14 (DSMZ)
ST   vWA: 14 (Cosmic-CLP; ECACC; JCRB; PubMed=20075370)
DI   NCIt; C4025; Esophageal adenocarcinoma
DI   ORDO; Orphanet_99976; Adenocarcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 33
//
RX   PubMed=11520067; DOI=10.1006/bbrc.2001.5400;
RA   Kan T., Shimada Y., Sato F., Maeda M., Kawabe A., Kaganoi J.-i.,
RA   Itami A., Yamasaki S., Imamura M.;
RT   "Gene expression profiling in human esophageal cancers using cDNA
RT   microarray.";
RL   Biochem. Biophys. Res. Commun. 286:792-801(2001).
//
RX   PubMed=20075370; DOI=10.1093/jnci/djp499;
RA   Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P.,
RA   Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K.,
RA   Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H.,
RA   Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Verification and unmasking of widely used human esophageal
RT   adenocarcinoma cell lines.";
RL   J. Natl. Cancer Inst. 102:271-274(2010).
//
RX   PubMed=23795680; DOI=10.1111/dote.12095;
RA   Boonstra J.J., Tilanus H.W., Dinjens W.N.M.;
RT   "Translational research on esophageal adenocarcinoma: from cell line
RT   to clinic.";
RL   Dis. Esophagus 28:90-96(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//